Investors
Investors > As an investment
The global eye care market is supported by powerful megatrends
Revenio is a leading turnkey solutions provider in the global eye care market. Our addressable market in ophthalmic diagnostic equipment is roughly USD 2.5 billion, the growth of which is supported by powerful megatrends. The need for eye care continues to increase globally in the coming years as the population ages and as health care environments and lifestyles evolve. Chronic lifestyle-related diseases such as diabetes are becoming more common and increasing the strain on healthcare, especially in developed countries.
Despite the growing need for eye care, the number of professionals in the field is decreasing. The increasing shortage of resources and skilled professionals means that intelligent eye care systems that improve efficiency, support clinical decision-making, and enable earlier diagnosis are becoming increasingly important. By enabling accurate refraction and more efficient screening and earlier diagnosis of eye diseases, Revenio addresses the critical challenges in eye care and improves the quality of life of millions of people around the world.
A comprehensive end-to-end diagnostic offering
Revenio offers a comprehensive product and software portfolio to help diagnose multiple ophthalmic pathologies, serving eye care professionals in optometry, optical retail and ophthalmology. Our market-leading ophthalmic diagnostic solutions include tonometers, fundus imaging devices, perimeters, microperimeters and software solutions under the iCare brand. By joining forces with Visionix in 2026, we expanded our portfolio to include optical coherence tomography (OCT), multimodal imaging, refraction systems, lensmeters and optical lab finishing equipment, significantly broadening our ability to support the complete diagnostic workflow and patient journey. Together, our technologies enable eye care professionals to access a broad range of solutions through a single trusted global partner.
The competitive advantages of our portfolio are built on four cornerstones: diagnostic reliability and repeatability of results, patient-centric solutions, seamless connectivity and efficient care pathways. These cornerstones are protected by patents, regulatory approvals, strong brands and seamlessly integrated software and algorithms.
Our products are available through distributors and our own sales network in more than 130 countries around the world, supporting eye care professionals and improving patient care worldwide. Our balanced global commercial footprint provides broad market access and enables the scalable commercialization of new solutions across customer segments.
Building the leading connected eye care platform together with Visionix
For decades, Revenio has combined clinical understanding, technological innovation and user-centric design to develop reliable, intuitive and accurate solutions for the early detection and monitoring of eye diseases. Our ability to develop market-leading products and solutions gives eye care professionals confidence that their diagnosis is correct and based on sufficient and reliable information.
We have made a remarkable journey from an equipment supplier to a global pioneer in eye diagnostics solutions. Joining forces with Visionix in 2026 marks the next phase in our evolution. By combining complementary diagnostic technologies with advanced software, telehealth, AI and data capabilities, we are building a seamlessly connected eye care platform. With this, we support the shift toward more efficient and service-oriented models of eye care, improve productivity, deepen customer relationships and deliver even better patient experiences and outcomes. Altogether, our solutions enable eye care professionals to focus on higher-value patient interactions and unlock new opportunities to grow their practices.
Through continuous innovation, integrated technologies and a deep understanding of clinical workflows, Revenio is building a sustainable competitive advantage and strengthening its position as a leading global eye care technology company.
Well positioned to accelerate growth and value creation
Revenio has proven its ability to grow profitably and sustainably for over a decade, and we want to continue on this path. We are at the forefront of creating a new generation of connected solutions that combine advanced technology and patient-centric care. This creates significant growth opportunities for us. With greater scale, portfolio breadth and channel reach through the Visionix transaction, we are even better positioned to compete in the eye care market – a global industry with strong long-term growth drivers and a high entry threshold.
Together with Visionix, we accelerate growth and value creation through a broader portfolio, expanded commercial reach, greater operational scale and targeted synergies. As part of the value creation process, we are targeting an annual growth rate corresponding to 3x the market growth rate, an EBITDA margin of 25% during 2028–2029 and an EBITDA margin approaching 30% beyond 2030. In addition, we are targeting more than EUR 20 million EBITDA uplift through joint value creation and synergies by the end of 2029.
Our success is based on the expertise, commitment and passion of our people. We promote a culture of cooperation and innovation that is open to continuous learning and development. Continued investments in our people, innovation, customer experience and commercial capabilities support our sustainable growth and strengthen our competitive position over the long term. This way, we will continue to keep the wonderful world visible to all.
Creating sustainable value through better eye care
Revenio promotes the healthcare sector’s transition toward more efficient care pathways and is committed to ensuring that all of its operations are ethically sustainable and transparent. We have systematically developed our sustainability efforts to integrate them more closely into our business processes and to increase the impact of our operations.
Through our innovations, we enhance preventive healthcare and improve accessibility, effectiveness and productivity in healthcare worldwide. The early diagnostics enabled by our devices help reduce the need for intensive treatments and lengthy care pathways, thereby contributing to a lower environmental footprint. Our products are durable and serviceable, reinforcing the principles of responsible manufacturing. By investing in our sustainability efforts and collaborating closely with our supply chain, we aim to develop our products with environmental considerations in mind. In doing so, we create sustainable value for both society and our investors.
Revenio Group Oyj | Härkähaankuja 7, 01730 Vantaa